Introducing
INFUSENSE
Leading the revolution in real-time
drug safety and monitoring
At Infusense, we believe the power of real-time clinical data saves lives. That’s why we pioneer novel biosensor technology that delivers immediate, accurate measurements for faster, more personalized care.
About Our Technology:
HemaSense
HemaSense is a first-in-class, hand-held device (like a glucometer used for checking blood sugar) that can be used by physicians to measure drug levels directly from a drop of blood or saliva, without sample processing.
How We're Different
- Places toxicity testing and therapeutic drug monitoring into the hands of physicians — no need to send a sample to the lab
- Simplifies sample collecting using a drop of blood or saliva — no syringes, sample tubes, etc., required
- Provides results within 5 minutes
Current Method:
2-5 Hours
HemaSense:
2-5 Minutes
How It Works
Biosensors convert biochemical information into electronic signals. HemaSense has a patented coating that allows many drugs to pass directly to the sensor, while blocking plasma proteins and other blood components.
Once in the membrane, the drug is oxidized by the electrode and generates a current that is directly proportional to its concentration. This tells the doctor the level of drug present in patients’ blood or saliva—enabling real-time clinical decision-making in order to:
- Ensure patient medication compliance
- Detect potential drug toxicity for 20+ drugs, including fentanyl, tricyclic anti-depressants, antipsychotics, and others
- Optimize medication dosing and therapeutic monitoring
Clinical Applications
Emergency Medicine: real-time detection and management of drug toxicity and accidental poisoning at immediate point-of-care.
Therapeutic Drug Monitoring: real-time testing and ongoing monitoring of drug levels to optimize medical decision-making for each patient.
Clinical Impact
The Challenge:
There are over 3 million Emergency Room visits annually related to drug poisoning. Fentanyl poisoning is the primary cause of the growing opioid crisis, the leading cause of death among Americans aged 18 to 45.
The Need:
There is a critical, unmet need to provide rapid results for fentanyl testing in the ER, at the point of contact. Currently, measuring drug levels and toxicity is time consuming, expensive, and requires many hours or days to obtain results from the laboratory.
Our Solution:
HemaSense has been described by physicians as “a game changer” in patient care—enabling rapid diagnosis of toxic drug overdoses and poisonings in minutes (not hours) and improving personalized medication dosing and monitoring for mental illness, epilepsy, and other conditions. It can be easily adopted to provide better care and save lives.
About Infusense
In 2012, Infusense launched and licensed the technology and patents for point-of-care drug detection from the University of Tennessee. In 2013, Infusense received a Department of Defense Small Business Innovation Research (SBIR) grant to apply its use to sedation and anesthesia.
In 2021, Infusense was awarded a prestigious National Science Foundation SBIR grant for rapid detection of drug toxicity and poisoning.
Leadership Team
Edward Chaum, MD, PhD
Founder and Chief Medical Officer
Eric Kriegstein, BA, MBA
Chief Executive Officer
Marcin Guzinski, PhD
Director of Engineering
Erno Lindner, PhD
Technical Advisor
Dr. Lindner, the R. Eugene Smith Professor of Biomedical Engineering and Professor of Chemistry at the University of Memphis, is an internationally recognized expert in the development and application of clinical biosensors and is an elected member of the Hungarian Academy of Sciences.